This week’s Biotech Stock Mailbag will address some current controversies and burning questions in our little corner of the investment world. Why the hell is Puma Biotechnology trading higher after the successful readout of Roche’s “APHINITY’ study of Perjeta in adjuvant breast cancer? What are the arguments for and against TG Therapeutics securing approval for ublituximab in high-risk chronic lymphocytic leukemia ? Did Aurinia Pharmaceuticals make a change to the primary endpoint of its phase III study of voclosporin in lupus nephritis? Are regulators okay with it? The March 2 announcement by Roche that Perjeta met the primary endpoint in the APHINITY study caused Puma shares to fall from $38 to an intraday low of $29.
Category: Cancer
Better Buy: Intuitive Surgical, Inc. vs. Accuray Incorporated
It’s no secret that with today’s aging Baby Boomer population, the future looks bright for investors in the healthcare industry. But not every healthcare company is created equal.
Old Cancer Drug Gets 1,000%-Plus Price Hike in Frugal U.K.
The chemotherapy known as busulfan is more than six decades old, and part of doctors’ standard arsenal against leukemia. It’s not scarce, and by all accounts, it should be dirt cheap.
This Promising Prostate Cancer Treatment Could Be a Game-Changer
Cancer is among the scariest diagnosis a person can receive. According to the American Cancer Society’s “Cancer Facts & Figures 2016” report, there were an estimated 1.69 million new cases of cancer diagnosed in 2016, along with a projected 595,690 cancer deaths.
This Promising Prostate Cancer Treatment Could Be a Game-Changer
Cancer is among the scariest diagnosis a person can receive. According to the American Cancer Society’s “Cancer Facts & Figures 2016” report, there were an estimated 1.69 million new cases of cancer diagnosed in 2016, along with a projected 595,690 cancer deaths.
3 Biotechs Likely to Be Acquired in 2017
The year is still young, but we’ve already seen acquisitions of Ariad and CoLucid . Which biotechs could be scooped up next in 2017? Here’s why Clovis Oncology The number of big companies battling to acquire Medivationin 2016 shows that the oncology space is hot.
Japan’s Takeda buys US cancer specialist Ariad for $5.2bn
Takeda’s offer is valued at more than 75% above Ariad’s closing share price on Friday – but some analysts says a rival bid cannot be ruled out. Cancer drugs are appealing to large pharmaceutical firms, who are prepared to pay high prices for companies with promising products in the pipeline.
Secretive Biotech Unicorn Moderna Unveils Pipeline, Financials
Moderna Therapeutics Inc., one of the best-funded private biotechnology companies in the U.S., unveiled its long-secret research and development pipeline on Monday, including experimental vaccines, cancer treatments and a cardiovascular therapy. The Cambridge, Massachusetts-based startup has about $1.3 billion in cash on hand from investors, pharmaceutical partners and government grants, according to a presentation Monday at the J.P.Morgan Chase & Co.
Merrimack Soars on $1 Billion Sale of Cancer Drugs to Ipsen
The Nasdaq-listed cancer drugs developer is up 43% in pre-market trading after promising shareholders special dividends worth more than its closing share price on Friday. Nasdaq-listed Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen for as much as $1.05 billion, including benchmark payments.
Ono Pharma’s Wild 2016 Ride Cuts Stock Valuation by $16 Billion
Having surged as much as 34 percent as of mid-April, the stock finished the year down more than 41 percent, marking its worst performance in more than 50 years. The swing reduced its market capitalization by about 1.87 trillion yen from a record high in April.
3 Myths About Marijuana Stocks
What do Hercules, Thor, centaurs, and marijuana stocks have in common? They’re all the subjects of myths. Most myths have at least a little bit of truth interspersed with a lot that is false.